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The chemokine CXCL12/SDF-1 and its receptor CXCR4 have been implicated in invasion, survival and proliferation of carcinoma
cells. Recently, CXCR7 was identified as a second receptor for CXCL12. We observed that CXCL12 promoted proliferation of
CT26 colon and KEP1 mammary carcinoma cells, and this was blocked when CXCR7 was downregulated by ‘intrakines’ or RNAi, but
not by CXCR4 inhibitors. The K1R mutant of CXCL12, which acts as a CXCR4 antagonist, also promoted proliferation through
CXCR7 and is therefore a selective CXCR7 agonist. The effect of CXCR7 was not due to reduced apoptosis, and CXCR7 mediated
chemotaxis of the carcinoma cells towards CXCL12. These results differ from those in a previous report on other carcinoma cells.
We conclude that CXCL12 can be a potent growth factor for carcinoma cells by acting on CXCR7. Nevertheless, we observed no
effect of complete and stable CXCR7 suppression on the growth of s.c. tumours or lung metastases of KEP1 and CT26 cells. A
CXCR7 inhibitor has been reported to reduce growth of other tumours. Our results indicate that this inhibitor may not be applicable
to therapy of all carcinomas.
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CXCR4, the receptor of the chemokine CXCL12/SDF-1, is
expressed in many tumours of multiple types including mammary
(Muller et al, 2001), colon (Zeelenberg et al, 2003) and pancreatic
(Saur et al, 2005) carcinoma, melanoma (Scala et al, 2005) and
brain tumours (Rubin et al, 2003). Expression often correlates with
the degree of malignancy and metastasis formation (Kaifi et al,
2005; Katayama et al, 2005; Kim et al, 2005; Scala et al, 2005;
Schimanski et al, 2005). Indeed, CXCR4 was demonstrated to be
required for experimental metastasis of mammary (Muller et al,
2001) and colon (Zeelenberg et al, 2003) carcinomas in the lungs
and liver. In addition, CXCR4 was among a set of proteins that, in
various combinations, promoted bone metastasis of mammary
carcinoma cells (Kang et al, 2003). Furthermore, CXCR4 is induced
by hypoxia and was proposed to be responsible for enhanced
malignancy of tumour cells in hypoxic areas (Schioppa et al, 2003;
Staller et al, 2003). This enhanced malignancy was generally
attributed to a role of CXCR4 in invasion, as the ligand CXCL12 is
present in many tissues and thought to promote migration into
those tissues (Muller et al, 2001). We and others have shown,
however, that chemokine receptors can also promote survival and
proliferation of tumour cells (Barbero et al, 2003; Rubin et al, 2003;
Zeelenberg et al, 2003; Katayama et al, 2005; Sutton et al, 2007;
Yang et al, 2007). For CT26 colon carcinoma cells, we provided
evidence that CXCR4 is required for the formation of liver and
lung metastases, not because of enhanced invasion but rather due
to an essential role in the outgrowth of the metastases (Zeelenberg
et al, 2003).
To demonstrate this involvement of CXCR4 in the CT26 cells, we
had expressed an ‘intrakine’ (Chen et al, 1997) that is the ligand
CXCL12 extended with a C-terminal KDEL sequence. The intrakine
binds to the KDEL receptor that retains resident proteins in the
endoplasmic reticulum (ER). The intrakine is therefore retained in
the ER, where it binds to newly synthesised CXCR4, which is also
trapped. Thus, we generated cells without cell surface CXCR4
(Zeelenberg et al, 2001, 2003) that did not grow out in the lungs
and liver. This intrakine approach was based on the generally held
assumption that CXCR4 was the only receptor for CXCL12.
Recently, however, the RDC1 protein was shown to be a second
CXCL12 receptor and was renamed CXCR7 (Balabanian et al, 2005;
Burns et al, 2006). It was described to be present on the surface of
many tumour cell types and on activated endothelial cells. CXCR7
promoted the survival of tumour cells in minimal medium by
preventing apoptosis and did not mediate chemotaxis towards
CXCL12. Importantly, a CXCR7 inhibitor greatly reduced the
growth of tumours generated from three different tumour cell lines
(Burns et al, 2006).
The CXCL12-KDEL intrakine should bind CXCR7 and, similar
to CXCR4, also trap CXCR7 in the ER. The results we obtained with
the CT26 colon carcinoma cells might thus involve CXCR7 rather
than, or in addition to, CXCR4. We therefore investigated this
possible role of CXCR7 in the CT26 cells as well as in Panc02
pancreatic carcinoma and in KEP1 (knockout/E-cadherin/P53)
mouse mammary carcinoma cells. The KEP tumours arose in p53
knockout mice in which the E-cadherin gene was disrupted in the
skin and mammary glands. They are quite similar to human
invasive lobular carcinomas with high metastatic capacity, and this
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sbehaviour is replicated by isolated KEP cells (Derksen et al, 2006).
We found that CXCR4 is in fact the receptor required for
metastasis. The cells do express CXCR7, however, and we observed
CXCR7-mediated effects of CXCL12 that we describe here.
We found that CXCL12 strongly enhanced proliferation, mediated
by CXCR7, and on some cells, also by CXCR4. This chemokine
is therefore a growth factor for carcinomas. Despite the
strong in vitro effects, however, we observed no difference in
growth rate in vivo of cells in which CXCR7 was completely
and stably suppressed, at least not in s.c. tumours and lung
metastases. This contrasts with the previously described effects
of a CXCR7 inhibitor on other tumour cells, including a carci-
noma (Burns et al, 2006). These observations are relevant
for the consideration to use this receptor as a target for cancer
therapy.
MATERIALS AND METHODS
Cell culture
The source of CT26 and Panc02 cells was described before (Meijer
et al, 2006). KEP1 cells were kindly provided by Dr J Jonkers of the
Netherlands Cancer Institute. All cells were cultured in DMEM
with 10% FCS or in Keratinocyte medium with 1% FCS, both with
100IUml
 1 of penicillin and 100mgml
 1 of streptomycin. The
Phoenix virus-packaging cell line (http://www.stanford.edu/group/
nolan) was cultured in DMEM with 10% FCS and 0.584gl
 1
L-glutamine, the T-cell hybridoma TAM2D2 as described
(Zeelenberg et al, 2001). Media, FCS and supplements were from
Life Technologies Ltd, Paisley, UK.
Generation and transduction of DNA constructs
The generation of the CXCL12-KDEL construct was described
previously (Zeelenberg et al, 2001). CXCL12 cDNA was generated
by PCR from this construct and the mutant K1R-CXCL12 from the
K1R-CXCL12-KDEL construct (Zeelenberg et al, 2001). Both were
cloned into the pLZRS-IRES-hygroEGFP vector (Zeelenberg et al,
2001). CXCL11-KDEL and CXCL10-KDEL were generated using a
one-step RT–PCR kit (Qiagen, Valencia, CA, USA) on RNA
isolated from mouse spleen, and inserted into the same vector. All
constructs were checked by sequencing. Vectors were transfected
into the virus-packaging Phoenix cells and the supernatant used to
infect tumour cells. Transduced cells were selected with 0.05
(CT26) or 0.1mgml
 1 (Panc02 and KEP1) hygromycin (Calbio-
chem-Novabiochem Corp., La Jolla, CA, USA) and cells with high
GFP levels were isolated by FACS sorting. Control cells were
transduced with the empty vector and sorted similarly. Luciferase
was introduced as described (Meijer et al, 2006). The RNAi
sequences GTGTTTCAATTCCAGCATA (CXCR4), CCCACTGTCT
ACTCAGGAA (CXCR7 RNAi.1: effective) and GAAATCATGTCC
TTATCTT (CXCR7 RNAi.3: ineffective) were incorporated into the
microRNA-30 sequence (Silva et al, 2005) and cloned into the LMP
(MSCV/LTRmiR30-PIG) vector (Open Biosystems, Huntsville, AL,
USA) that also contains the GFP cDNA under the control of the
PGK promoter. For details see the literature provided by
the supplier: http://www.openbiosystems.com/RNAi/Retroviral
CloningVectors. The chosen sequences were derived from the
RNAi Codex (http://codex.cshl.edu/scripts/newmain.pl). For trans-
duction, we used Phoenix cells as above. Puromycin (1.75mgml
 1;
Sigma-Aldrich, St Louis, MO, USA) was used for selection and cells
with high GFP levels were FACS sorted.
Generation of CXCR7 antiserum
The peptide DYAEPGNYSDINWP (mouse CXCR7, 7–21) was
synthesised by the in-house facility and coupled to keyhole limpet
haemocyanin. A polyclonal antiserum was generated in rabbits by
standard procedures.
Flow cytometry
Cultures were trypsinised and 10
6 cells were incubated for 60min
with CXCR4 mAb 12G5 (R&D systems, Minneapolis, MN, USA) or
with the CXCR7 antiserum and next with PE-conjugated antibodies
against mouse or rabbit IgG, respectively, and analysed using a
Becton Dickinson FACSCan using CellQuest software. Cells from
tumours were isolated and treated as described (Meijer et al, 2006)
and gated to exclude dead and GFP-negative cells so that only
tumour cells that are GFP positive were analysed.
Proliferation assay
CT26 cells (5 10
3 or 10
4 per well) or Panc02 or KEP1 cells
(5 10
4 per well) were seeded in several 96-well plates in DMEM
with 10% FCS or Keratinocyte medium with 1% FCS. Luciferase
activity was measured every 24h after the addition of 10mlo f
15mgml
 1 D-luciferin, using a Xenogen IVIS imaging system (see
below: in vivo bioluminescence). Each time, only one plate was
measured and a different plate was assessed for each of the time
points, so that each plate was measured only once. The data were
normalised to 1 at day 0. As this assay did not involve any washing
steps, it was quite reproducible, with standard deviations of
triplicates of B0.02%. To some wells, 100ngml
 1 CXCL12
(PeproTech Inc., Rocky Hill, NJ, USA) was added or supernatants
of CT26 cells transfected with either CXCL12 or K1R-CXCL12 that
had been grown in either 10 or 1% FCS. Supernatants of similarly
cultured CT26 cells were used as controls. In some experiments,
125ngml
 1 AMD3100 (Sigma, St Louis, MO, USA) or 1ngml
 1
TC14012 was added. The TC14012 was synthesised by the in-house
peptide facility.
Apoptosis assay
Adherent cells were trypsinised and both the detached cells and
those floating in the medium were collected, fixed with 70%
ethanol, stained with propidium iodide and analysed by FACS,
without gating. Cells in the G1 (n) and G2/M (2n) phases of the cell
cycle could be distinguished. Apoptotic cells have a DNA content
lower than n. As a positive control, apoptosis was induced by UV
irradiation (50Jm
 2, 16h before the assay).
Chemotaxis
For the carcinoma cells, chemotaxis was assayed as described
(Meijer et al, 2006) with 100ngml
 1 of CXCL12 in the lower well.
Chemotaxis of T-cell hybridoma cells was measured as described
(Zeelenberg et al, 2001).
Tumour formation in vivo
All procedures involving animals were approved by the Animal
Welfare Committee. For CT26 cells, we used syngeneic Balb/c mice
and for KEP1 cells, nude mice, both 6–8 weeks old. Cells (10
3)
were dispersed in 0.5ml Matrigel (Becton Dickinson, Franklin
Lakes, NJ, USA) at 01C and injected s.c. into mice anaesthetised
with 3% 1-chloro-2,2,2-triflouroethyl-diflouromethyl-ether (iso-
flurane). Alternatively, we injected 0.2ml PBS containing 10
5 cells
into a tail vein or 0.1ml containing 10
6 cells subcutaneously.
In vivo bioluminescence imaging
D-Luciferin (Xenogen, Alameda, CA, USA) was dissolved at
15mgml
 1 in sterile PBS and stored at  201C. Animals were
anaesthetised with 3% isoflurane. Luciferin solution was injected
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si.p. (0.01ml per g body weight). Light emission was measured
5min later, using a cooled CCD camera (IVIS; Xenogen), coupled
to Living Image acquisition and analysis software over an
integration time of 2min. Signal intensity was quantified as the
total counts measured over the region of interest.
RESULTS
CXCL12 promotes proliferation of CT26 carcinoma cells,
but not through CXCR4
We have previously shown that CT26 colon carcinoma cells require
CXCR4 for outgrowth of metastases (Zeelenberg et al, 2003). The
cells have no surface CXCR4 in vitro (see Figure 1C) but acquire it
in vivo. The cells do not express the CXCR4 ligand CXCL12, as
determined by RT–PCR (data not shown). We reasoned that if
these cells would produce this ligand, in vivo growth of metastases
might be further promoted, and therefore we transfected the
CXCL12 cDNA. Much to our surprise, the resulting CXCL12-
producing cells proliferated faster than control CT26 cells in vitro,
despite the absence of CXCR4. In addition, we transfected the K1R
mutant of CXCL12, which is a potent inhibitor of CXCR4 (Crump
et al, 1997). Remarkably, the mutant also increased proliferation.
This indicated that the increase in proliferation was mediated by
an, at the time, unknown second CXCL12 receptor.
To demonstrate that the effect was due to the expressed
proteins, the supernatants were added to wild-type CT26 cells.
Proliferation was increased by both supernatants to a similar
extent as recombinant CXCL12 (Figure 1A). This was not only seen
in minimal medium (1% FCS) but also in optimal medium (10%
FCS) in which proliferation was already quite fast. In either of
these circumstances, the percentage of apoptotic cells was very
low, as assessed by FACS analysis of propidium iodide-stained
cells (Figure 1C). The percentage varied between 1 and 4%, as
compared with B50% in UV-irradiated cells that were used as
positive controls, and was not lower in CXCL12-treated cells,
showing that the effect could not be due to the suppression of
apoptosis.
To confirm that the K1R mutant is a CXCR4 inhibitor, we
studied chemotaxis of TAM2D2 T-cell hybridoma cells (Zeelenberg
et al, 2001) towards CXCL12. As shown in Figure 1B, this is
blocked by the CXCR4 inhibitors AMD3100 (Donzella et al, 1998)
and TC14012 (Tamamura et al, 2001), and therefore mediated by
CXCR4. K1R-CXCL12 did not induce chemotaxis and it inhibited
chemotaxis towards intact CXCL12, confirming that it is a CXCR4
antagonist. The two CXCR4 inhibitors did not influence the
CXCL12-induced enhancement of proliferation of CT26 cells at
concentrations at which they completely inhibited chemotaxis
mediated by CXCR4 (Figure 1B).
The CXCL12 concentration in the supernatant was
B100ngml
 1, based on a comparison of dose–response curves
with recombinant CXCL12 (data not shown). The mutant was
expressed at similar levels, as deduced from co-expressed GFP, and
its concentration in the supernatant is likely roughly comparable,
as deduced from B35% inhibition of chemotaxis towards
100ngml
 1 CXCL12 (Figure 1B). For proliferation, concentrations
were saturating, as the effect was the same at 50% dilution.
For both, the effect was reduced by B60% at 10% dilution
(data not shown), indicating that the affinity for CXCR7 was
comparable.
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Figure 1 (A) Proliferation of CT26 colon carcinoma cells in super-
natants of CT26 cells, either or not supplemented with 100ngml
 1
recombinant CXCL12, or in supernatants of CT26 cells expressing
CXCL12 or the K1R-CXL12 mutant. The supernatants contained either
1 or 10% FCS. Changes in cell numbers were measured by biolumines-
cence of these luciferase-expressing cells, after the addition of luciferin.
Shown are the results of one of the two experiments with virtually identical
results. The s.e.m. are extremely small (B0.02%) and error bars are
therefore not shown. For clarity, we used markers that are far larger than
the error bars, and they were slightly displaced when overlapping to make
them all visible. (B) Verification of effects on CXCR4 by CXCR4-mediated
chemotaxis of TAM2D2 T-cell hybridoma cells in 2h towards different
concentrations (ngml
 1) of recombinant CXCL12, towards supernatants
(sup) of control CT26 cells or of CXCL12- or K1R-CXCL12-expressing
CT26 cells, or to 100ngml
 1 CXCL12 added to the K1R-CXCL12-
containing supernatant. AMD3100 (125ngml
 1) and TC14012 (1ngml
 1)
inhibit completely at these concentrations, whereas they have no effect on
CXCL12-induced proliferation. Shown are the results of one of the four
experiments with similar results. (C) FACS analysis of CXCR4 and CXCR7
on CT26 cells grown in vitro and of PI-stained cells, either UV-irradiated or
not 16h before.
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sEffect of CXCL12 on proliferation of CT26 cells is mediated
by CXCR7
While this work was in progress, the identification of a second
CXCL12 receptor was reported: the orphan receptor RDC1/
CMKOR1, which was renamed CXCR7 (Balabanian et al, 2005;
Burns et al, 2006). We established by RT–PCR that CT26 and
KEP1 cells expressed CXCR7 (data not shown). Next, we generated
a polyclonal antiserum against a peptide that is the mouse
homologue of the epitope of an anti-human CXCR7 mAb
(Balabanian et al, 2005). Using this antiserum, we detected CXCR7
on the surface by FACS analysis. As shown in Figure 1C, CT26 cells
that were devoid of CXCR4 did express CXCR7 in vitro.
Next, we tested CXCL12 on KEP1 mammary carcinoma cells
(Derksen et al, 2006). The KEP1 cells did express not only CXCR4
in vitro, but also CXCR7 (Figure 2A). They grow slower than CT26
cells, but again we observed enhanced proliferation although the
effect was somewhat less pronounced than in CT26 cells
(Figure 2B), and the extent of stimulation was again similar in 1
and 10% FCS. The data shown in Figure 2B were from cells in 1%
FCS. The K1R mutant had a similar effect (Figure 2B), indicating
that CXCR4 was not involved. The concentration of the ligands was
saturating, as a 50% reduction led to identical results. CXCL12
similarly enhanced the proliferation of human carcinoma cell lines,
including CAPAN1 pancreatic carcinoma and MDA-MB-231
mammary carcinoma (data not shown). The MDA-MB-231 variant
we used did not express CXCR4 in vitro, again showing that
CXCR4 was not involved.
RNAi would have been the most straightforward approach to
discriminate between functions of CXCR4 and CXCR7. As this was
initially not successful, and also to obtain independent evidence,
we again used the intrakine approach (see Introduction). As
CXCR7 also binds CXCL11, whereas CXCR4 does not (Burns et al,
2006), a CXCL11-KDEL intrakine should trap CXCR7 in the ER
selectively. However, CXCL11 also binds the CXCR3 chemokine
receptor that may be expressed by carcinoma cells (Goldberg-
Bittman et al, 2004). We therefore used a CXCL10-KDEL intrakine
as control, because CXCL10 also binds CXCR3 but not CXCR7
(Burns et al, 2006). We could not express either of these intrakines
in CT26 cells even though we did successfully transfect several
other intrakines: CXCL12-KDEL (Zeelenberg et al, 2003), CXCL13-
KDEL (Meijer et al, 2006) and recently, also CXCL16-KDEL (Meijer
et al, 2008), in these cells. This suggested that CXCR3 is required
for their survival and/or growth. However, we did express the two
KEP1 mammary carcinoma
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Figure 2 (A) Effects of intrakines or RNAi on CXCR4 and CXCR7 surface levels of KEP1 mammary carcinoma cells. Open histograms: negative controls
(second antibody only for CXCR4 or preimmune serum and second antibody for CXCR7). Grey filled histograms: either CXCR4 mAb (upper row) or
CXCR7 antiserum (lower row). (B) Effect of intrakines and RNAi on proliferation of KEP1 cells in 1% FCS-containing supernatants, as in Figure 1.
Concentrations of both CXCL12 and mutant were saturating, as the effects were similar at 50% dilution (not shown). Results are from one of the two
experiments with virtually identical results.
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sintrakines in KEP1 cells and both at similar levels, as determined
by FACS analysis of GFP that was co-expressed from the
bicistronic vector. CXCL11-KDEL completely blocked transport
to the cell surface of CXCR7, but not CXCR4, resulting in cells
without cell surface CXCR7 (Figure 2A). CXCL10-KDEL had no
such effect (Figure 2A). The CXCR7-deficient cells did not respond
at all to intact or mutant CXCL12 (Figure 2B), providing strong
evidence that CXCR7 was the involved receptor. CXCL12-KDEL
downregulated both CXCR4 and CXCR7 (Figure 2A), and because
of the latter effect also blocked the (K1R)-CXCL12-induced
proliferation (Figure 2B).
Later, we did achieve knockdown of CXCR7 using an shRNAmir
vector that encodes a natural microRNA containing the RNAi
sequence (Silva et al, 2005). Sorting for high levels of co-expressed
GFP yielded KEP1-RNAi.1 cells in which CXCR7 was completely
suppressed (Figure 2A). As a control, we used another CXCR7
sequence (RNAi.3) that was completely ineffective (Figure 2A), as
well as a CXCR4 RNAi that completely suppressed CXCR4 but not
CXCR7 (Figure 2A), all expressed at similar levels as based on GFP
fluorescence (not shown). Again, the CXCR7-deficient cells did not
respond at all to CXCL12, whereas the control cells did (Figure 2B),
demonstrating that CXCR7 is the involved receptor. CXCR7
RNAi.1 had the same effect in CT26 cells (not shown).
Both CXCR7 and CXCR4 enhance proliferation in Panc02
pancreatic carcinoma cells
We next tested Panc02 pancreatic carcinoma cells that express
both CXCR4 and CXCR7 (Figure 3A). However, the CXCR7 levels
were lower than on KEP1 cells, whereas the CXCR4 levels were
comparable or higher (compare Figures 2A and 3A). Again,
CXCL12 enhanced proliferation (Figure 3B and C). In these cells,
this was mediated by both CXCR7 and CXCR4, as a complete
knockdown of either (Figure 3A) caused a partial inhibition
(Figure 3B and C), whereas the CXCL12-KDEL intrakine, which
completely eliminated both from the surface (Figure 3A), reduced
proliferation to control levels (Figure 3B). In line with this notion,
K1R-CXCL12 had a smaller effect than intact CXCL12, and this was
fully blocked by CXCR7 but not CXCR4 knockdown (Figure 3D),
again showing that the K1R-CXCL12 mutant activates only CXCR7.
We conclude that both receptors can trigger growth-promoting
signals.
In all these experiments, proliferation was measured by
bioluminescence. As this involves no washing steps, the data are
quite reproducible with s.e.m. of B0.2%. The CXCL12-induced
increases in cell number observed after 7 days were therefore
always highly significant (Po0.0001). To demonstrate that
bioluminescence reflects cell number, we trypsinised the cells
from the wells after measuring bioluminescence and counted the
cells. An example is given in Figure 3C. The results were similar
and the P-values of the differences were o0.0001.
CXCR7 mediates chemotaxis towards CXCL12
CXCR7 was reported to differ from CXCR4 in that it did not induce
chemotaxis towards CXCL12 (Burns et al, 2006). We tested this
using the CXCR4-negative CT26 cells and found that CXCL12
Panc02 pancreatic carcinoma, 10% FCS
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CXCR4 CXCR7
102 103 10 10 102 103 10 102 103 10 102 103
Relative cell number (bioluminescence)
6
5
4
3
2
1
0
35
12345 6 days 7
Control + CXCL12
CXCR4-RNAi +CXCL12
CXCR7-RNAi.1 + CXCL12
CXCL12-KDEL + CXCL12
Cells without CXCL12
Cells per well (×103) after 7 days
25
15
5
Control CXCR4-
RNAi
CXCR7-
RNAi.1
CXCL12-
KDEL
P<10–4 P<10–4 P<10–4 P=0.5
No CXCL12  + CXCL12 
Relative cell number (bioluminescence) D
Control cells CXCR4-RNAi
4
3
2
1
4
3
2
1
CXCR7-RNAi.1 CXCL12-KDEL
0123456 1234 d a y s 6
Control + K1R-CXCL12 + CXCL12
Figure 3 (A) Effects of intrakines or RNAi on CXCR4 and CXCR7
surface levels of Panc02 pancreatic carcinoma cells. Open histograms:
negative control (preimmune serum and second antibody for CXCR7).
Grey filled histograms: CXCR4 mAb; black filled histograms: CXCR7
antiserum. For clarity, only the negative control for the polyclonal antiserum
is shown. Therefore, the fluorescence of CXCR4-suppressed cells seems
lower than this control. In reality, they coincide with the proper control.
(B) Proliferation of these cells in the presence or absence of 100ngml
 1
CXCL12, as measured by bioluminescence. (C) The number of cells per
well after 7 days in the same experiment as in panel B, manually counted
after trypsinisation. (D) The effect of CXCL12-KDEL intrakine and CXCR4
or CXCR7 RNAi on the proliferation of Panc02 cells in supernatants of
control or CXCL12- or K1R-CXCL12-expressing CT26 cells, as in
Figure 1A. Results in panels B–D are of one of the three experiments
with almost identical results.
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spotently induced chemotaxis, which was not inhibited by the
CXCR4 inhibitors AMD3100 and TC14012 (Figure 4A). Chemo-
taxis was maximal at 100ngml
 1 and half-maximal at 40ngml
 1
(not shown). The K1R CXCR4 mutant was equally effective,
showing again that it is a CXCR7-specific agonist. Migration was
inhibited by 60% in cells in which Gi protein signalling was fully
blocked by pertussis toxin, showing that it is mediated by both Gi-
dependent and Gi-independent mechanisms (not shown). Cells
expressing CXCL12-KDEL or CXCR7-RNA.1, in which CXCR7 was
suppressed, did not migrate towards CXCL12 (Figure 4B). CXCR4
RNAi had no effect, as expected for cells that do not express
CXCR4 in vitro. This chemotaxis was comparable to the extent to
that induced by CXCL11 (not shown). This was reduced by B50%
by CXCR7 RNAi, the remainder likely due to CXCR3, the presence
of which was not further studied. We conclude that CXCR7 signals
are clearly able to trigger migration but that this apparently
depends on the cell type.
No effect of CXCR7 on tumour growth in vivo
To test the effects on growth in vivo, we subcutaneously injected
cells in Matrigel. On account of the instant solidification at 371C,
cells remained dispersed and initially grew as separate single
tumours. All cells expressed luciferase and growth was monitored
by measuring bioluminescence after the injection of luciferin. As
shown in Figure 5A, KEP1 control cells (expressing GFP from an
empty vector) and other CXCR7-positive KEP1 controls (the
ineffective CXCR7 RNAi.3 and CXCL10-KDEL) grew at the same
rate as the CXCR7-deficient cells (CXCR7 RNAi.1 and CXCL11-
KDEL). The Td for controls was 54.3h (s.e.m., 0.7) and for the
CXCR7-deficient cells 53.1h (s.e.m., 0.8). The difference was
clearly not significant (P¼0.27). In cells isolated from tumours 4
weeks after injection, CXCR7 was still completely suppressed
(Figure 5B). (Please note that the FACS profiles differ from those
in vitro (see Figure 2), quite likely due to the collagenase
160
160
120
80
40
A
B
CT26 colon carcinoma: chemotaxis towards CXCL12
number of cells per field
Inhibitor: none AMD3100 TC14012
120
80
40
Control
+ CXCL12
Control CXCL12-KDELCXCR7-RNAi.1 CXCR4-RNAi
Figure 4 Chemotaxis of CT26 colon carcinoma cells in 6h towards
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 1 CXCL12. (A) In the presence or absence of the CXCR4
inhibitor AMD3100 (125ngml
 1) or TC14012 (1ngml
 1). Data shown
are of one experiment of two with similar results. (B) The effect of
CXCL12-KDEL intrakine and CXCR4 or CXCR7 RNAi. Results are
averages of two experiments. Error bars represent s.e.m.
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Figure 5 Effect of CXCR7 suppression on growth of KEP1 mammary
carcinoma cells in vivo.( A) In Matrigel plugs. CXCR7-positive controls:
untransfected, CXCL10-KDEL and CXCR7-RNAi.3 (see Figure 2A), n¼2f o r
each, total n¼6. CXCR7-negative cells: CXCR7-RNAi.1, CXCL11-KDEL (see
Figure 2A), n¼2 for each, total n¼4. Error bars represent s.e.m. (B)C X C R 7
levels on cells isolated from plugs. Note that background is higher for these
collagenase-treated cells than for untreated cultured cells (compare negative
controls with Figure 2A). The profile of CXCR7-deficient cells coincides with
the negative controls, showing that the effects of intrakine and RNAi are stable
for at least 4 weeks in vivo.( C) The growth of s.c. injected cells (without
Matrigel), as in panel A. CXCR7-deficient cells now also include cells
expressing CXCL12-KDEL. Total of both control and deficient cells, n¼6.
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streatment. The relevant comparison is with control cells of which
the CXCL10-KDEL cells are shown).
This lack of effect might be due to the Matrigel that might
contain factors that compensate for the lack of CXCR7 signalling.
We therefore injected cells subcutaneously, without Matrigel,
similarly as the Lewis lung carcinoma cells of which the growth
was reported to be reduced by a CXCR7 inhibitor (Burns et al,
2006). Again, we saw no effect of CXCR7 deficiency (Figure 5C).
The growth rate was remarkably similar to that in Matrigel:
Td¼54.0h (s.e.m., 1.1) for controls and 54.0h for the CXCR7-
deficient cells (s.e.m., 1.4; P¼0.48). Finally, we injected CT26 cells
into a tail vein and found that lung metastases of CXCR7-deficient
cells grew at the same rate as control cells (Figure 6A). The Td for
controls was 73.2h (s.e.m., 3.6) and for the CXCR7-deficient cells,
it was 77.2h (s.e.m., 1.2). The difference was not significant
(P¼0.34). We conclude that the presence of CXCR7 does not lead
to enhanced proliferation in vivo, at least not in s.c. tumours and
in lung metastases. The tumour cells were isolated from lung
metastases after 24 days and analysed by FACS (Figure 6B). Thus,
we confirmed our previous observation (Zeelenberg et al, 2003)
that CT26 cells, which are devoid of CXCR4 in vitro, do express
CXCR4 in vivo. Furthermore, we found that CXCR7 was still
completely suppressed in the CXCR7-RNAi cells, so that the lack of
effect on growth is not due to loss of the RNAi effect during the
experiment.
DISCUSSION
CXCR7, the newly discovered second receptor of CXCL12, was
reported to be expressed by several different tumour cell types and
to mediate a CXCL12-induced increase of survival of mammary
carcinoma cells in minimal medium. CXCR7 did not promote
proliferation (Burns et al, 2006). We show here that these
conclusions are not generally valid for carcinomas. In mouse
CT26 colon, KEP1 mammary and Panc02 pancreatic carcinoma
cells, CXCL12 increased proliferation and this was mediated by
CXCR7, as we conclude based on the following observations. First,
CT26 cells express CXCR7 but not CXCR4 in vitro. Second, the
K1R mutant of CXCL12, which is a CXCR4 antagonist (Crump
et al, 1997), also induced proliferation. Third, downregulation of
CXCR7, by either the CXCL11-KDEL intrakine or RNAi, abolished
the effects. CXCL10-KDEL (that should affect CXCR3, if present,
similarly as CXCL11-KDEL) and an ineffective RNAi sequence
served as controls that were expressed at similar levels but did not
inhibit.
It is particularly noteworthy that the K1R mutant of CXCL12
triggers CXCR7. Lysine at position 1 in CXCL12 is not required for
binding to CXCR4, but is essential for the triggering of CXCR4
signals (Crump et al, 1997). The K1R mutant binds CXCR4 but
does not signal and therefore acts as a powerful antagonist. Indeed,
it strongly inhibited the chemotaxis of T-cell hybridoma cells
towards CXCL12. In contrast, it enhanced proliferation, by
activation of CXCR7, to a similar extent as the intact chemokine.
K1R-CXCL12 is therefore a selective agonist for CXCR7.
CXCR7 is not the only CXCL12 receptor that can trigger
enhanced growth. CXCR4 can also mediate this effect, as
demonstrated using specific inhibitors and antibodies (Barbero
et al, 2003; Rubin et al, 2003; Katayama et al, 2005; Sutton et al,
2007; Yang et al, 2007). In fact, we show here that in Panc02
pancreatic carcinoma cells, CXCR4 contributes to the CXCL12-
induced enhancement of proliferation. In KEP1 cells, the effect is
mediated exclusively by CXCR7. This may be due to the relatively
high CXCR7 levels (compare Figures 2A and 3A).
It was previously reported that the number of MDA-MB-435
human mammary carcinoma cells expanded in the presence of
CXCL12, an effect mediated by CXCR7 (Burns et al, 2006). This
occurred in minimal medium containing only 1% FCS, in which
extensive apoptosis was observed in the absence of CXCL12. The
increase in cell number was due to the prevention of apoptosis by
the CXCR7 signals, and apparently not due to an enhanced
proliferation. Our results with the CT26 and KEP1 cell lines were
quite different. We observed only minimal apoptosis in 1% FCS.
Moreover, an equally strong increase in proliferation occurred
even in ‘optimal’ medium containing 10% FCS. Furthermore, it
was reported that CXCR7 did not mediate chemotaxis of MCF-7
mammary carcinoma cells towards CXCL12 (Burns et al, 2006).
This is, however, not generally true as the CXCR4-negative CT26
colon carcinoma cells did migrate towards CXCL12, mediated by
CXCR7, as was in fact previously demonstrated for T lymphocytes
(Balabanian et al, 2005). We conclude that CXCR7 is able to
initiate powerful proliferation- and migration-inducing signals,
but that the response apparently differs between cell types.
Furthermore, we conclude that the chemokine CXCL12 can act
as a powerful growth factor by signals transmitted by either or
both CXCR4 and CXCR7. This adds to our previous observation
that the chemokine CXCL13 can act as a growth factor for
carcinoma cells that express its receptor CXCR5 (Meijer et al,
2006), suggesting that chemokines may be more generally involved
in tumour growth.
Surprisingly, despite the strong in vitro effects, CXCR7 did not
influence tumour growth in vivo, at least not in s.c. tumours and in
lung metastases. Both the CXCL11-KDEL intrakine and RNAi
caused complete and stable downregulation of CXCR7, but neither
had any effect on growth rates in s.c. Matrigel plugs in vivo. This
CT26 colon carcinoma
A Growth of lung metastases
Relative bioluminescence
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105
11 14 16 days 19 21 23
Control CXCR7-deficient (CXCR7-RNAi.1)
B CXCR4 and CXCR7 on cells isolated after 24 days
CT26 control CXCR7-RNAi.1
CXCR4 CXCR7 CXCR4 CXCR7
10 102 103 10 102 103 10 102 103 10 102 103
Figure 6 (A) Proliferation of lung metastases of CT26 colon carcinoma
cells after tail vein injection of mice with control cells (n¼5) or CXCR7-
deficient cells (CXCR7 RNAi.1, n¼5). Error bars represent s.e.m.
(B) FACS analysis of CXCR4 and CXCR7 in CT26 cells isolated from
lung metastases after 24 days. Although the cells are devoid of CXCR4 in
vitro, they do express CXCR4 in vivo. The complete suppression of CXCR7
by RNAi is maintained throughout these 24 days.
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smight be attributed to the absence of CXCL12 in these artificially
induced tumours, which may lack the proper tumour environ-
ment. Supplying the ligand did not seem to have an effect either,
however, as the CT26 cells in which CXCL12 or the selective
CXCR7 agonist K1R-CXCL12 was expressed did not grow faster in
vivo (data not shown), although we can not be sure that
production of these chemokines was actually maintained in vivo.
Importantly, we also found no evidence for CXCR7 involvement in
s.c. tumours, established in a manner comparable with the Lewis
lung carcinomas that were shown to be affected by a CXCR7
inhibitor (Burns et al, 2006). Finally, also growth of lung
metastases was not influenced by the suppression of CXCR7.
Recently, in vivo effects of CXCR7 RNAi on other tumours were
reported (Miao et al, 2007). Tumour growth was reduced to
different extents. For instance, the final tumour weight of s.c. Lewis
lung carcinomas was reduced by B50%, whereas the effect on 4T1
mammary carcinoma was larger. Our results clearly indicate that
this is not generally applicable to carcinomas, at least not in s.c.
tumours or lung metastases. This does not exclude an effect of
CXCR7 in other circumstances. In fact, the expression of CXCR7
on many tumour cells and the ubiquitous presence of CXCL12 in
tissues suggest that this should occur, perhaps in tissues that are
particularly rich in CXCL12 or in particular stages of tumour
development. It may also depend on whether, and to what extent,
the tumour cells produce autocrine CXCL12. It should, however,
not be expected that CXCR7 inhibitors would be applicable to
therapy of all carcinomas.
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